![]() Such progress by a small biotech is rare in the industry today," said Musial. "I am impressed with the caliber of Promontory's management and the fact that the company is already in three Phase 2 clinical trials. Stan's extensive financial experience, with both public and private biotech companies, and familiarity with equity investors and capital markets overall bolsters our capabilities and positions us well as we plan our Series B capital round," said Promontory President and Chief Executive Officer Robert Fallon. "We welcome Stan to the Promontory team at an exciting and pivotal time in our corporate development. Musial brings over 25 years of financial, strategic and managerial experience with public and private biotechnology companies, with a demonstrated history in capital raising, IPO execution, mergers and acquisitions, corporate development and investor relations. Musial, CPA, MBA, as Chief Financial Officer. ![]() 28, 2022 /PRNewswire/ - Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today announced the appointment of Stanley J. ![]() ![]() Experienced financial executive in building corporate value and capital fundraising ![]()
0 Comments
Leave a Reply. |